LinkBack URL
About LinkBacks
Reply With QuoteWhat do u think is the potential of this company?
KKUR - Early Cancer Detection
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company?s systems measure the unique genomic characteristic common to all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology vastly superior to anything in existence and that it will become the undisputed gold standard for cancer detection worldwide.
The Company?s technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
ChromoCure, Inc. Launches Nationwide Diagnostic Lab Partnership Program
RENO, NV, Nov 03, 2009 (MARKETWIRE via COMTEX) -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced its partnership program for cancer diagnostic laboratories and research centers.
Industry pathologists and cancer diagnostic research centers may request the company's partnership package and materials at:
Services - ChromoCure...
Pathology labs will receive ChromoCure's CS200 Chromosomal Scanner installed on their premises without cost. ChromoCure will provide training, material, and marketing guidance. Established insurance codes exist for ease of billing and collections. The ChromoCure CS200 can deliver immediate revenue to pathologists.
Cancer research centers may purchase the company's equipment or use one of the company's network pathology labs to perform chromosomal scans. Preferred pricing will be extended to all cancer research partners. Purchasers of the CS200 chromosomal scanner will receive a favorable upgrade price to the CS300 series when released.
The company has established this special program to expand it network of pathology labs as well as promote its science and technology with cancer research centers.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Investor Relations:
Contact:
ChromoCure, Inc.
info@chromocure.com
Tel 1.775.636.6548
What do u think is the potential of this company?
check VRMLQ (Vermillon) and you will understand
any info about FDA classification?
Chromecure technology doesn t need FDA approval
I just started watching this one... Any idea why there was such a big dump or was it dilution??
Can you please comment on why this one does not need any FDA approval or FDA reporting.
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis.
did they submit a 510k application to the FDA?
FDA Approvals: The Company does not require FDA approval because its systems function as inhouse
assays and do not make diagnoses but only provide for each cell in the sample the genomic data and
characteristic unique to all cancers. These assays are widely accepted as scientifically valid and are relied upon
routinely throughout the healthcare system. They are regulated by the Centers for Medicare & Medicaid Services
(CMS) under the Clinical Laboratory Improvement of 1988 (CLIA). Furthermore, the company does not treat, cure,
or diagnose any disease. We offer laboratory services to detect the presence or absence of advanced chromosomal
imbalances within the nucleus of cells. The pathologist, doctor, or other licensed health-care practitioner makes a
diagnosis to the patient.
Once they go for the CURE... then FDA approvals will be needed.... but they can sell these NOW!!!!
Posting Permissions 